Edesa Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>EB</div>
EDSA -- USA Stock  

USD 8.14  0.06  0.73%

While some traders are getting carried away by overanalyzing healthcare space, it is reasonable to go over Edesa Biotech against current market trends. For some short-term oriented investors Edesa Biotech may be the right move right now, Let's take a closer look. The returns on the market and returns on Edesa Biotech appear slightly correlated for the last few months. Weak basic indicators of the company may also suggest signs of long term losses for Edesa investors. The next fiscal quarter end is expected on the 30th of September 2020. The stock is undergoing an active upward rally.
Published over a month ago
View all stories for Edesa Biotech | View All Stories
Will Edesa Biotech (NASDAQ:EDSA) price continue to rise in September?
This firm's average rating is Strong Buy from 1 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Edesa Biotech market sentiment investors' perception of the future value of Edesa. Let us look at a few aspects of Edesa technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Edesa Biotech. In general, we focus on analyzing Edesa Biotech stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Edesa Biotech's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Edesa Biotech's intrinsic value. In addition to deriving basic predictive indicators for Edesa Biotech, we also check how macroeconomic factors affect Edesa Biotech price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.

How does Edesa Stands against Peers?

Analyzing Edesa Biotech competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Edesa Biotech across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Edesa Biotech Competition Details

How Edesa utilizes its cash?

To perform a cash flow analysis of Edesa Biotech, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Edesa Biotech is receiving and how much cash it distributes out in a given period. The Edesa Biotech cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Edesa Biotech Net Cash Flow from Operations is projected to increase significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (1.48 Million)

Edesa Biotech exotic insider transaction detected

Legal trades by Edesa Biotech insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Edesa insider trading alert for general transaction of common shares by Nijhawan Pardeep, Chief Executive Officer, on 18th of September 2020. This event was filed by Edesa Biotech Inc with SEC on 2020-09-18. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Edesa Biotech Downside Variance

Edesa Biotech has current Downside Variance of 52.03. Downside Variance (or DV) is measured by target semi-variance and is termed downside volatility. It is expressed in percentages and therefore allows for rankings in the same way as variance. One way to view downside volatility is the annualized variance of returns below the target.

Downside Variance is the probability-weighted squared below-target returns. The squaring of the below-target returns has the effect of penalizing failures at an exponential rate. This is consistent with observations made on the behavior of individual decision-making under.

Downside Variance 
 = 
SUM(RET DEV)2 
N(ER) 
 = 
52.03
SUM = Summation notation
RET DEV = Actual returns deviation over selected period
N(ER) = Number of points with returns less than expected return for the period
Let's now compare Edesa Biotech Downside Variance to its closest peers:
EDSA
EQ
DVAX
DYAI
DNLI
EDSA52.02699129281309
EQ95.43
DVAX36.7
DYAI28.02
DNLI19.71

Will Edesa Biotech growth be rational after the rise?

Current standard deviation is at 17.17. Edesa Biotech is displaying above-average volatility over the selected time horizon. Investors should scrutinize Edesa Biotech independently to ensure intended market timing strategies are aligned with expectations about Edesa Biotech volatility.

Our Final Take On Edesa Biotech

Whereas many other companies within the biotechnology industry are still a little expensive, even after the recent corrections, Edesa Biotech may offer a potential longer-term growth to investors. The inconsistency in the assessment between current Edesa valuation and our trade advice on Edesa Biotech is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Edesa Biotech.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Edesa Biotech. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com